These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. HDAC inhibitors in models of inflammation-related tumorigenesis. Glauben R; Sonnenberg E; Zeitz M; Siegmund B Cancer Lett; 2009 Aug; 280(2):154-9. PubMed ID: 19101082 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Blanchard F; Chipoy C Drug Discov Today; 2005 Feb; 10(3):197-204. PubMed ID: 15708534 [TBL] [Abstract][Full Text] [Related]
6. Prospects: histone deacetylase inhibitors. Dokmanovic M; Marks PA J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937 [TBL] [Abstract][Full Text] [Related]
7. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Hess-Stumpp H Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394 [TBL] [Abstract][Full Text] [Related]
9. Quinazolines as novel anti-inflammatory histone deacetylase inhibitors. Lin Z; Murray PM; Ding Y; Denny WA; Ferguson LR Mutat Res; 2010 Aug; 690(1-2):81-8. PubMed ID: 20558185 [TBL] [Abstract][Full Text] [Related]
10. Development of histone deacetylase inhibitors for cancer treatment. Marchion D; Münster P Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177 [TBL] [Abstract][Full Text] [Related]
11. The role of histone deacetylases in asthma and allergic diseases. Bhavsar P; Ahmad T; Adcock IM J Allergy Clin Immunol; 2008 Mar; 121(3):580-4. PubMed ID: 18234319 [TBL] [Abstract][Full Text] [Related]
12. Potent stimulation of gene expression by histone deacetylase inhibitors on transiently transfected DNA. Nan X; Hyndman L; Agbi N; Porteous DJ; Boyd AC Biochem Biophys Res Commun; 2004 Nov; 324(1):348-54. PubMed ID: 15465025 [TBL] [Abstract][Full Text] [Related]
13. Impact of protein acetylation in inflammatory lung diseases. Ito K; Charron CE; Adcock IM Pharmacol Ther; 2007 Nov; 116(2):249-65. PubMed ID: 17720252 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to histone deacetylase inhibitors. Lee JH; Choy ML; Marks PA Adv Cancer Res; 2012; 116():39-86. PubMed ID: 23088868 [TBL] [Abstract][Full Text] [Related]
15. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Zhu WG; Lakshmanan RR; Beal MD; Otterson GA Cancer Res; 2001 Feb; 61(4):1327-33. PubMed ID: 11245429 [TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory effects of [6]-shogaol: potential roles of HDAC inhibition and HSP70 induction. Shim S; Kim S; Choi DS; Kwon YB; Kwon J Food Chem Toxicol; 2011 Nov; 49(11):2734-40. PubMed ID: 21864631 [TBL] [Abstract][Full Text] [Related]
17. [Assay for inhibitory activity of histone deacetylase]. Yoshida M Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors: multifunctional anticancer agents. Liu T; Kuljaca S; Tee A; Marshall GM Cancer Treat Rev; 2006 May; 32(3):157-65. PubMed ID: 16516391 [TBL] [Abstract][Full Text] [Related]
19. Acetylation of proteins as novel target for antitumor therapy: review article. Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351 [TBL] [Abstract][Full Text] [Related]